6YG Stock Overview A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. More details
Rewards Risk Analysis See All Risk Checks {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Capture your thoughts, links and company narrative
Immunocore Holdings plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Immunocore Holdings Historical stock prices Current Share Price US$27.80 52 Week High US$68.50 52 Week Low US$26.40 Beta 0.77 1 Month Change -4.14% 3 Month Change -9.74% 1 Year Change -58.51% 3 Year Change 34.95% 5 Year Change n/a Change since IPO -27.42%
Recent News & Updates
Immunocore Holdings plc Announces Cessation of Travis Coy as Director Jan 08 Immunocore Holdings plc Appoints Travis Coy as Executive Vice President and Head of Corporate Development
Immunocore Holdings plc Announces First Patient Dosed in the Phase 1 Trial of IMC-P115C Dec 24
Immunocore Announces Treatment of First Patient in the Phase 1/2 Trial of IMC-R117C Targeting PIWIL1 in Advanced Gastrointestinal Cancers Dec 18
European Organisation for Research and Treatment of Cancer and Immunocore Holdings plc Announces Enrolment of First Patient Onto Phase 3 Adjuvant Trial in Oveal Melanoma Dec 11
Third quarter 2024 earnings released: EPS: US$0.17 (vs US$0.018 in 3Q 2023) Nov 10 See more updates
Immunocore Holdings plc Announces Cessation of Travis Coy as Director Jan 08 Immunocore Holdings plc Appoints Travis Coy as Executive Vice President and Head of Corporate Development
Immunocore Holdings plc Announces First Patient Dosed in the Phase 1 Trial of IMC-P115C Dec 24
Immunocore Announces Treatment of First Patient in the Phase 1/2 Trial of IMC-R117C Targeting PIWIL1 in Advanced Gastrointestinal Cancers Dec 18
European Organisation for Research and Treatment of Cancer and Immunocore Holdings plc Announces Enrolment of First Patient Onto Phase 3 Adjuvant Trial in Oveal Melanoma Dec 11
Third quarter 2024 earnings released: EPS: US$0.17 (vs US$0.018 in 3Q 2023) Nov 10
New major risk - Revenue and earnings growth Nov 08
Immunocore Presents Phase 1 Data of Brenetafusp, an Immtac Bispecific Targeting Prame, in Patients with Ovarian Cancer Sep 16 Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer Aug 29
Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.35 loss in 2Q 2023) Aug 11
Immunocore Holdings plc to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
New minor risk - Share price stability Jul 26
New major risk - Revenue and earnings growth Jul 18
Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma Jun 18 Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director
Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma May 29
Now 22% undervalued after recent price drop May 22
New major risk - Revenue and earnings growth May 11
First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.43 loss in 1Q 2023) May 08
Insufficient new directors Apr 21
Immunocore Holdings plc, Annual General Meeting, May 23, 2024 Apr 13
Full year 2023 earnings released: US$1.13 loss per share (vs US$1.09 loss in FY 2022) Feb 29
Immunocore Holdings plc to Report Q4, 2023 Results on Feb 28, 2024 Feb 22
Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023 Jan 30
Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline Jan 05
New minor risk - Share price stability Nov 28
Third quarter 2023 earnings released: EPS: UK£0.04 (vs UK£0.13 in 3Q 2022) Nov 08
New major risk - Revenue and earnings growth Nov 01
Second quarter 2023 earnings released: UK£0.29 loss per share (vs UK£0.14 loss in 2Q 2022) Aug 11
Immunocore Holdings plc to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
First quarter 2023 earnings released: UK£0.35 loss per share (vs UK£0.37 loss in 1Q 2022) May 11
Forecast breakeven date moved forward to 2024 Mar 14
Forecast breakeven date pushed back to 2025 Mar 03
Full year 2022 earnings released: UK£0.90 loss per share (vs UK£3.10 loss in FY 2021) Mar 02
Immunocore Holdings plc Provides Revenue Guidance for the Fourth Quarter and Twelve Months Ended December 31, 2022 Jan 11 Immunocore Holdings plc Announces the Addition of Three New ImmTAC Product Candidates
Forecast to breakeven in 2025 Dec 31
Immunocore Holdings plc Presents Ovarian Cancer Expansion Data for ImmTAC® candidate IMC-C103C targeting MAGE-A4 Dec 10
An unknown buyer acquired a 5% stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Malin Corporation plc (ISE:MLC) for approximately €150 million. Dec 08
Third quarter 2022 earnings released: EPS: UK£0.13 (vs UK£0.69 loss in 3Q 2021) Nov 10
High number of new directors Oct 31
Second quarter 2022 earnings released Aug 11
Immunocore Holdings plc to Report Q2, 2022 Results on Aug 10, 2022 Aug 04
High number of new directors Aug 01 Immunocore Holdings plc announced that it has received $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P., Baker Bros. Advisors LP and another investor Jul 22
Immunocore Holdings plc announced that it expects to receive $139.999988 million in funding from RTW Investments, LP, Rock Springs Capital Management LP, General Atlantic Service Company, L.P. Jul 19
Immunocore Announces Dosing of First Patient with ImmTAV(R) Bispecific for HIV Jul 12
High number of new directors Jul 02
Immunocore Announces the Presentation of Initial Data from the Phase 1 Immtav® Trial for Chronic Hepatitis B At the EASL International Liver Congress™ Jun 26
Immunocore Holdings plc Appoints Siddharth (Sid) Kaul as A Non-Executive Member of Its Board of Directors Jun 10
Immunocore Holdings plc Announces UK Medicines and Healthcare Products Regulatory Agency, Australian Therapeutic Goods Administration and Health Canada Approves Kimmtrak® (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma Jun 09 Immunocore Holdings plc Presents New Data on KIMMTRAK (tebentafusp-tebn) in metastatic Cutaneous Melanoma (mCM) and metastatic Uveal Melanoma (mUM) at the 2022 American Society of Clinical Oncology Annual Meeting Jun 07
Immunocore Announces Upcoming Presentations At the 2022 American Society of Clinical Oncology Annual Meeting May 27
First quarter 2022 earnings released: UK£0.37 loss per share (vs UK£0.76 loss in 1Q 2021) May 12
Immunocore Holdings plc, Annual General Meeting, May 12, 2022 Apr 15
European Commission Approves Immunocore Holdings plc's KIMMTRAK (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma Apr 05
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 04
Immunocore Holdings plc Receives Positive CHMP Opinion for KIMMTRAK (Tebentafusp) for the Treatment of Unresectable or Metastatic Uveal Melanoma Feb 26
Immunocore Holdings plc Announces Approval from the United States Food and Drug Administration of KIMMTRAK for the Treatment of Unresectable or Metastatic Uveal Melanoma Jan 27
Third quarter 2021 earnings released: UK£0.69 loss per share (vs UK£0.064 loss in 3Q 2020) Nov 11
Immunocore Announces Publication of Phase 3 Data Comparing tebentafusp with Investigator’s Choice in the New England Journal of Medicine Sep 24
Immunocore Presents Data At the European Society for Medical Oncology (Esmo) Congress 2021 Demonstrating A Reduction in Circulating Tumor DNA (ctDNA) While on Tebentafusp Is Associated with Overall Survival in the Phase 2 Clinical Trial Sep 21
Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma Sep 09
An unknown buyer acquired stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Medigene AG (XTRA:MDG1) for $4.7 million. Sep 02
Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma Aug 25
Second quarter 2021 earnings released: UK£0.75 loss per share (vs UK£0.63 loss in 2Q 2020) Aug 13 Shareholder Returns 6YG DE Biotechs DE Market 7D -4.8% 1.2% 2.3% 1Y -58.5% -5.6% 16.7%
See full shareholder returns
Return vs Market: 6YG underperformed the German Market which returned 16.7% over the past year.
Price Volatility Is 6YG's price volatile compared to industry and market? 6YG volatility 6YG Average Weekly Movement 5.6% Biotechs Industry Average Movement 5.7% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 6YG has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 6YG's weekly volatility (6%) has been stable over the past year.
About the Company Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Show more Immunocore Holdings plc Fundamentals Summary How do Immunocore Holdings's earnings and revenue compare to its market cap? 6YG fundamental statistics Market cap €1.36b Earnings (TTM ) -€45.26m Revenue (TTM ) €285.08m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6YG income statement (TTM ) Revenue US$296.31m Cost of Revenue US$208.75m Gross Profit US$87.56m Other Expenses US$134.61m Earnings -US$47.05m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.94 Gross Margin 29.55% Net Profit Margin -15.88% Debt/Equity Ratio 116.1%
How did 6YG perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/12 02:45 End of Day Share Price 2025/02/12 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Immunocore Holdings plc is covered by 22 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jack Allen Baird Peter Lawson Barclays Olga Smolentseva Bryan Garnier & Co
Show 19 more analysts 